About: SCHOOL Model and New Targeting Strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SCHOOL Model and New Targeting Strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SCHOOL Model and New Targeting Strategies
Creator	Sigalov, Alexander
Source	Medline; PMC
abstract	Protein-protein interactions play a central role in biological processes and thus are an appealing target for innovative drug design and development. They can be targeted by small molecule inhibitors, peptides and peptidomimetics, which represent an alternative to protein therapeutics that carry many disadvantages. In this chapter, I describe specific protein-protein interactions suggested by a novel model of immune signaling, the Signaling Chain HOmoO Ligomerization (SCHOOL) model, to be critical for cell activation mediated by multichain immune recognition receptors (MIRRs) expressed on different cells of the hematopoietic system. Unraveling a long-standing mystery of MIRR triggering and transmembrane signaling, the SCHOOL model reveals the intrareceptor transmembrane interactions and interreceptor cytoplasmic homointeractions as universal therapeutic targets for a diverse variety of disorders mediated by immune cells. Further, assuming that the general principles underlying MIRR-mediated transmembrane signaling mechanisms are similar, the SCHOOL model can be applied to any particular receptor of the MIRR family. Thus, an important application of the SCHOOL model is that global therapeutic strategies targeting key protein-protein interactions involved in MIRR triggering and transmembrane signal transduction may be used to treat a diverse set of immune-mediated diseases. This assumes that clinical knowledge and therapeutic strategies can be transferred between seemingly disparate disorders, such as T-cell-mediated skin diseases and platelet disorders, or combined to develop novel pharmacological approaches. Intriguingly, the SCHOOL model unravels the molecular mechanisms underlying ability of different human viruses such as human immunodeficiency virus, cytomegalovirus and severe acute respiratory syndrome coronavirus to modulate and/or escape the host immune response. It also demonstrates how the lessons learned from viral pathogenesis can be used practically for rational drug design. Application of this model to platelet collagen receptor signaling has already led to the development of a novel concept of platelet inhibition and the invention of new platelet inhibitors, thus proving the suggested hypothesis and highlighting the importance and broad perspectives of the SCHOOL model in the development of new targeting strategies.
has issue date	2008-01-01(xsd:dateTime)
bibo:doi	10.1007/978-0-387-09789-3_20
bibo:pmid	19065798
has license	no-cc
sha1sum (hex)	bc0859f34bfb9b1e75220c42362947892dfdb6f7
schema:url	https://doi.org/10.1007/978-0-387-09789-3_20
resource representing a document's title	SCHOOL Model and New Targeting Strategies
has PubMed Central identifier	PMC7123132
has PubMed identifier	19065798
schema:publication	Multichain Immune Recognition Receptor Signaling
resource representing a document's body	covid:bc0859f34bfb9b1e75220c42362947892dfdb6f7#body_text
is schema:about of	named entity 'development' named entity 'Strategies' named entity 'alternative' named entity 'inhibitors' named entity 'drug design' named entity 'interactions' named entity 'experimental evidence' named entity 'HIV' named entity 'therapeutic targets' named entity 'mechanisms of action' named entity 'CD86' named entity 'adenylyl cyclase' named entity 'therapeutic targets' named entity 'peptidomimetics' named entity 'protein-protein interactions' named entity 'CYTO' named entity 'dimers' named entity 'antibodies' named entity 'TCR' named entity 'multivalent' named entity 'positively charged' named entity 'fusin' named entity 'structural biology' named entity 'Structural analogs' named entity 'TCR' named entity 'NF-AT' named entity 'viral pathogenesis' named entity 'GPVI' named entity 'CYTO' named entity 'platelet' named entity 'LASV' named entity 'TCRa' named entity 'gp41' named entity 'immunomodulatory' named entity 'peptides' named entity 'target cells' named entity 'CYTO' named entity 'G-protein-coupled receptors' named entity 'pathogenesis' named entity 'SARS-CoV' named entity 'Transmembrane' named entity 'gp41' named entity 'B-cell' named entity 'T-cell' named entity 'HTLV-1' named entity 'solubility' named entity 'molecular mechanisms' named entity 'signal transduction' named entity 'peptidomimetics' named entity 'signal transduction' named entity 'peptide' named entity 'arthritis' named entity 'cytoplasmic domain' named entity 'HIV' named entity 'CYTO' named entity 'trans-autophosphorylation' named entity 'SARS-CoV' named entity 'TCR' named entity 'CD4' named entity 'CYTO' named entity 'CYTO' named entity 'critical role' named entity 'negatively charged' named entity 'ligand' named entity 'medical conditions' named entity 'complementation' named entity 'adapter protein' named entity 'NK cell' named entity 'CYTO' named entity 'protein-protein interactions' named entity 'collagen' named entity 'transduce' named entity 'TCR' named entity 'signal transduction' named entity 'integral membrane receptor' named entity 'small molecule' named entity 'peptide' named entity 'nucleocapsid' named entity 'LUVs' named entity 'CD4' named entity 'immune cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software